Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company. Through its subsidiary, the company is engaged in developing and commercializing cancer immunotherapies in the United States. The company is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.
  • TickerRCUS
  • ISINUS03969F1093
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ResearchPool Subscriptions

Get the most out of your insights

Get in touch